MX382582B - Anticuerpos contra cúmulo de diferenciación 48 (cd48) y sus conjugados. - Google Patents

Anticuerpos contra cúmulo de diferenciación 48 (cd48) y sus conjugados.

Info

Publication number
MX382582B
MX382582B MX2017011432A MX2017011432A MX382582B MX 382582 B MX382582 B MX 382582B MX 2017011432 A MX2017011432 A MX 2017011432A MX 2017011432 A MX2017011432 A MX 2017011432A MX 382582 B MX382582 B MX 382582B
Authority
MX
Mexico
Prior art keywords
conjugates
differentiation
antibodies against
against cluster
cluster
Prior art date
Application number
MX2017011432A
Other languages
English (en)
Spanish (es)
Other versions
MX2017011432A (es
Inventor
Kristine Gordon
Lori Westendorf
Timothy Lewis
Original Assignee
Seagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seagen Inc filed Critical Seagen Inc
Publication of MX2017011432A publication Critical patent/MX2017011432A/es
Publication of MX382582B publication Critical patent/MX382582B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
MX2017011432A 2015-03-18 2016-03-17 Anticuerpos contra cúmulo de diferenciación 48 (cd48) y sus conjugados. MX382582B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562134981P 2015-03-18 2015-03-18
PCT/US2016/022943 WO2016149535A1 (en) 2015-03-18 2016-03-17 Cd48 antibodies and conjugates thereof

Publications (2)

Publication Number Publication Date
MX2017011432A MX2017011432A (es) 2017-11-10
MX382582B true MX382582B (es) 2025-03-13

Family

ID=56919489

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011432A MX382582B (es) 2015-03-18 2016-03-17 Anticuerpos contra cúmulo de diferenciación 48 (cd48) y sus conjugados.

Country Status (16)

Country Link
US (2) US10722592B2 (enExample)
EP (2) EP3662933A1 (enExample)
JP (2) JP6892826B2 (enExample)
KR (1) KR20170128256A (enExample)
CN (1) CN107530422B (enExample)
AU (1) AU2016232839B2 (enExample)
BR (1) BR112017019617A2 (enExample)
CA (1) CA2976740A1 (enExample)
DK (1) DK3270965T3 (enExample)
EA (2) EA201992756A3 (enExample)
ES (1) ES2795818T3 (enExample)
IL (1) IL254027B (enExample)
MX (1) MX382582B (enExample)
SG (1) SG11201706786UA (enExample)
WO (1) WO2016149535A1 (enExample)
ZA (1) ZA201705935B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180134351A (ko) 2016-03-25 2018-12-18 시애틀 지네틱스, 인크. 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
JP7527787B2 (ja) 2017-03-24 2024-08-05 シージェン インコーポレイテッド グルクロニド薬物－リンカーの調製のためのプロセスおよびその中間体
MX2020012718A (es) 2018-05-29 2021-02-16 Intocell Inc Derivados de benzodiazepinas novedosos y usos de los mismos.
TW202519270A (zh) 2018-06-07 2025-05-16 美商思進公司 喜樹鹼結合物
WO2020089687A2 (en) 2018-10-31 2020-05-07 Intocell, Inc. Fused heterocyclic benzodiazepine derivatives and uses thereof
AU2020219732A1 (en) * 2019-02-05 2021-08-05 Seagen Inc. Anti-CD228 antibodies and antibody-drug conjugates
BR112022005114A2 (pt) 2019-10-04 2022-06-21 Seagen Inc Anticorpo, composição farmacêutica, métodos para tratar câncer e para produzir um conjugado anticorpo-fármaco e um anticorpo, ácido nucleico, vetor, célula hospedeira, e, conjugado anticorpo-fármaco
WO2021067820A1 (en) 2019-10-04 2021-04-08 Seagen Inc. Formulation of antibody-drug conjugate
JP2022550851A (ja) 2019-10-04 2022-12-05 シージェン インコーポレイテッド カンプトテシンペプチドコンジュゲート
IL297167A (en) 2020-04-10 2022-12-01 Seagen Inc Charging variant connectors
EP4251648A2 (en) 2020-11-24 2023-10-04 Novartis AG Anti-cd48 antibodies, antibody drug conjugates, and uses thereof
EP4251208A1 (en) * 2020-11-24 2023-10-04 Novartis AG Mcl-1 inhibitor antibody-drug conjugates and methods of use
EP4308170A1 (en) 2021-03-18 2024-01-24 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
JP2024520562A (ja) 2021-05-28 2024-05-24 シージェン インコーポレイテッド アントラサイクリン抗体コンジュゲート
KR20250004952A (ko) 2022-03-17 2025-01-08 씨젠 인크. 캄프토테신 접합체
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
US12178876B2 (en) 2023-04-18 2024-12-31 Astrazeneca, Ab Conjugates comprising cleavable linkers
TW202525851A (zh) 2023-08-15 2025-07-01 瑞典商阿斯特捷利康公司 包含可切割連接子的軛合物
WO2025090774A1 (en) 2023-10-24 2025-05-01 Seagen Inc. Chemotherapeutic compounds and methods of use
WO2025149947A1 (en) 2024-01-12 2025-07-17 Seagen Inc. Antibody-drug conjugates
WO2025185617A1 (en) * 2024-03-05 2025-09-12 Hutchmed Limited Linker, antibody-drug conjugate and use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
CA2249998A1 (en) 1996-03-27 1997-10-02 Crc For Biopharmaceutical Research Pty. Ltd. The use of antibodies against cd48 for the treatment of t and b cell lymphomas and leukemias
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
ES2544527T3 (es) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
CN103394083B (zh) 2003-11-06 2017-07-18 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
US20070178072A1 (en) 2004-03-31 2007-08-02 Kirin Beer Kabushiki Kaisha Method for inducing differentiation of regulatory t cells usinggip-anchored protein agonist and pharmaceutical composition therefor ( as amended
EP1747237A4 (en) 2004-04-16 2008-05-21 Macrogenics Inc SPECIFIC GAMMA FC ANTIBODIES AND METHODS OF USING THE SAME
EP2722051B1 (en) 2005-07-07 2018-11-07 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
DK3248613T3 (da) * 2005-07-18 2022-03-14 Seagen Inc Beta-glucuronid-lægemiddel-linkerkonjugater
SI2532681T1 (sl) * 2005-12-20 2015-03-31 Sbi Biotech Co., Ltd. Protitelo proti-ILT7
CA2702555A1 (en) 2007-10-19 2009-04-23 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
NZ585559A (en) 2007-11-13 2012-11-30 Teva Biopharmaceuticals Usa Inc Humanized antibodies against tl1a
US9029636B2 (en) 2008-02-05 2015-05-12 Monsanto Technology Llc Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits
WO2010117059A1 (ja) * 2009-04-10 2010-10-14 国立大学法人大阪大学 形質細胞の腫瘍性増殖をきたす疾患の治療薬
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
AR083044A1 (es) * 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
CA2830923A1 (en) * 2011-04-15 2012-10-18 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
WO2013134743A1 (en) 2012-03-08 2013-09-12 Halozyme, Inc. Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
NZ724892A (en) * 2012-05-15 2018-04-27 Seattle Genetics Inc Self-stabilizing linker conjugates
KR102645430B1 (ko) * 2013-10-15 2024-03-11 씨젠 인크. 개선된 리간드-약물 컨쥬게이트 약물동력학을 위한 peg화된 약물-링커

Also Published As

Publication number Publication date
CN107530422B (zh) 2021-09-21
US20180092984A1 (en) 2018-04-05
EP3662933A1 (en) 2020-06-10
AU2016232839B2 (en) 2021-02-25
EA035374B1 (ru) 2020-06-03
JP6892826B2 (ja) 2021-06-23
ZA201705935B (en) 2021-01-27
MX2017011432A (es) 2017-11-10
IL254027A0 (en) 2017-10-31
US20200289661A1 (en) 2020-09-17
ES2795818T3 (es) 2020-11-24
CA2976740A1 (en) 2016-09-22
AU2016232839A1 (en) 2017-08-31
HK1248538A1 (zh) 2018-10-19
IL254027B (en) 2021-05-31
EA201992756A3 (ru) 2020-06-30
JP2018509908A (ja) 2018-04-12
KR20170128256A (ko) 2017-11-22
EA201792055A1 (ru) 2018-01-31
JP2020141700A (ja) 2020-09-10
EP3270965A1 (en) 2018-01-24
WO2016149535A1 (en) 2016-09-22
EA201992756A2 (ru) 2020-03-31
US10722592B2 (en) 2020-07-28
BR112017019617A2 (pt) 2018-05-22
EP3270965B1 (en) 2020-05-06
CN107530422A (zh) 2018-01-02
SG11201706786UA (en) 2017-09-28
DK3270965T3 (da) 2020-06-08
EP3270965A4 (en) 2018-09-05

Similar Documents

Publication Publication Date Title
MX382582B (es) Anticuerpos contra cúmulo de diferenciación 48 (cd48) y sus conjugados.
CY1125241T1 (el) Υποδορια σκευασματα αντισωματων anti-cd38 και οι χρησεις τους
MX385456B (es) Anticuerpos cd123 y conjugados de los mismos.
ZA202107931B (en) Anti-tau antibodies and methods of use
MX377710B (es) Anticuerpos monoclonales contra bcma.
PH12019502283A1 (en) Anti-lag3 antibodies
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
ECSP17070399A (es) Anticuerpos contra icos
MX385915B (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
AR114112A1 (es) Anticuerpos de glipicano 3 y conjugados de los mismos
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
DOP2019000064A (es) Anticuerpo que se une específicamente a pd-1 y fragmento funcional del mismo
MX2019006330A (es) Anticuerpos anti-tau y metodos de uso.
CY1125400T1 (el) Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων
MX2021007119A (es) Metodos para producir anticuerpos heterodimericos.
PH12020551791A1 (en) Methods for the production of methacrylates
EP4524563A3 (en) Flow based assays for therapeutics
CL2017000320S1 (es) Porción de carrete.
UA114708U (uk) Тяговий привід електробуса
EA201892257A1 (ru) Анти-cd3 антитела и способы применения